Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 11/20 | 0.83 |
| ▸ | CHRM3 known ✓ | P20309 | 10/20 | 0.83 |
| ▸ | CHRM2 | P08172 | 11/20 | 0.83 |
| ▸ | CHRM4 | P08173 | 10/20 | 0.83 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buzepide SCHEMBL3498775 | 0.78 | CHRM3 (0.57) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| Tricyclamol SCHEMBL30573196 | 0.78 | CHRM2 (0.58) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| Tricyclamol SCHEMBL2734572 | 0.77 | CHRM2 (0.56) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| Fenpiverinium SCHEMBL1650132 | 0.76 | CHRM3 (0.55) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| Fenpiverinium SCHEMBL23654 | 0.75 | CHRM3 (0.53) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| Tiemonium SCHEMBL24577 | 0.72 | CHRM3 (0.47) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| Etipirium SCHEMBL916033 | 0.71 | CHRM2 (0.67) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL560935 | 0.70 | SMN1; SMN2 (0.61) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| Etipirium SCHEMBL29388403 | 0.69 | CHRM2 (0.69) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL9935058 | 0.68 | ALDH1A1 (0.51) | CHRM2CHRM1CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114685594-A | Preparation method of rocuronium bromide starting material (LK-7) single crystal | 北京满格医药科技有限公司 | 2022-07-01 | — | — | CN | claimed |
| US-12595318-B2 | — | — | 2026-04-07 | — | — | US | disclosed |
| US-20250346934-A1 | SELF-ASSEMBLY ENZYME SYSTEM SUPPLYING A-KETOGLUTARATE AND APPLICATION THEREOF IN CATALYTIC SYNTHESIS OF 4-HYDROXYISOLEUCINE | UNIV JIANGNAN (CN) | 2025-11-13 | — | — | US | disclosed |
| US-12441892-B2 | Low dielectric silica powder, resin composition containing the silica powder, and method for manufacturing low dielectric silica powder | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-10-14 | — | — | US | disclosed |
| US-20240342340-A1 | MULTILAYER STRUCTURE USING CHEMICALLY CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-10-17 | — | — | US | disclosed |
| US-12098290-B2 | Low dielectric silica powder, resin composition containing the silica powder, and method for manufacturing low dielectric silica powder | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20240174863-A1 | LOW DIELECTRIC SILICA POWDER, RESIN COMPOSITION CONTAINING THE SILICA POWDER, AND METHOD FOR MANUFACTURING LOW DIELECTRIC SILICA POWDER | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-05-30 | — | — | US | disclosed |
| US-20240174772-A1 | NOVEL CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-30 | — | — | US | disclosed |
| CN-117801048-A | Preparation method of rocuronium bromide intermediate | 成都新恒创药业有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117801048-A | Preparation method of rocuronium bromide intermediate | 成都新恒创药业有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-116874636-A | Novel cross-linked alginic acid | 持田制药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| CN-112236457-B | Novel cross-linked alginic acid | 持田制药株式会社 | 2023-08-29 | — | — | CN | disclosed |
| US-20220409773-A1 | TRANSPLANTATION DEVICE USING CHEMICALLY CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-12-29 | — | — | US | disclosed |
| EP-3737684-B1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-11-16 | — | — | EP | disclosed |
| WO-2022145419-A1 | MULTILAYER STRUCTURE USING CHEMICALLY CROSSLINKED ALGINIC ACID | 持田製薬株式会社 | 2022-07-07 | — | — | WO | disclosed |
| CN-114685594-A | Preparation method of rocuronium bromide starting material (LK-7) single crystal | 北京满格医药科技有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-114685594-A | Preparation method of rocuronium bromide starting material (LK-7) single crystal | 北京满格医药科技有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-114685594-A | Preparation method of rocuronium bromide starting material (LK-7) single crystal | 北京满格医药科技有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-216254192-U | Flower seedling raising substrate | 河南艾农生物科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114302749-A | Transplanting device using chemically crosslinked alginic acid | 持田制药株式会社 | 2022-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595318-B2 | — | ALG1, ALG8, FUCA1 | CHRM1 3733/4885CHRM3 3798/4885CHRM2 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.